iPS Cells-The Triumphs and Tribulations.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human clinical data.
PubMed 29563461 · doi:10.3390/dj4020019
What was done
This narrative review summarizes the history of induced pluripotent stem cell (iPSC) development, their biological properties (pluripotency and self-renewal), their applications in disease modeling, drug discovery, and regenerative cellular therapies, and the translational challenges facing their use in regenerative dentistry.
What was found
The abstract reports no numerical data. It qualitatively notes that while patient-derived iPSCs reduce immune rejection risks for regenerative medicine, generation of these cells remains slow, inefficient, technically difficult, and unsafe for human clinical applications.
Why it matters
It outlines the potential role of patient-specific stem cell technology in regenerative dentistry while emphasizing major biological and safety hurdles that prevent current clinical use.
Limits
As a non-systematic narrative review, the paper provides no original empirical measurements, clinical data, or quantitative synthesis. Specific dental protocols and outcomes are not detailed in the abstract.
Cited by
- supports Shinya Yamanaka won the Nobel Prize for the discovery of Yamanaka factors.